Skip to main content
EJNMMI Research

Table 2 Raw baseline toxicity prior to PRRT and at screening (i.e. prior to [166Ho]-radioembolization)

From: Inflammatory markers and long term hematotoxicity of holmium-166-radioembolization in liver-dominant metastatic neuroendocrine tumors after initial peptide receptor radionuclide therapy

 

CTCAE grade

Pre-PRRT

Baseline

1–2

3

4

1–2

3

4

Thrombocyte

3/30

  

12/31

  

Neutrophil

2/26

  

1/31

  

Lymphocyte

 

1/27

 

11/31

7/31

 

Leukocyte

3/30

  

11/31

  

Hemoglobin

13/30

  

17/31

  
  1. Values are n/available observed patients with the designated toxicity grade
Back to article page